论文部分内容阅读
目的：观察单用兰索拉唑的抗酸治疗，与合用阿莫西林的抗幽门螺杆菌（Ｈｐ）治疗，对难治性十二指肠溃疡（ＤＵ）的近期愈合率及１年复发率。方法：将８０例难治性ＤＵ随机分为兰索拉唑组和合用阿莫西林组，观察及对比两组４周愈合率。兰索拉唑组愈合且Ｈｐ阳性的病例再随机分为维持组和停药组。合用阿莫西林组溃疡愈合，Ｈｐ阴性的病例进入Ｈｐ根除组，Ｈｐ阳性的进入Ｈｐ未根除组；观察对比４组的１年复发率。结果：４周愈合率兰索拉唑组为８５％，合用阿莫西林组为８８％，两组对比无显著性差异（Ｐ＞０．０５）；１年复发率维持组为６％，停药组为４７％，两组比较有显著性差异（Ｐ＜０．０１）；Ｈｐ根除组为５％，Ｈｐ未根除组为４４％，两组对比有显著性差异（Ｐ＜０．０１）；Ｈｐ根除组与维持组对比无显著性差异（Ｐ＞０．０５）。
OBJECTIVE: To observe the anti-acid therapy with lansoprazole alone and amoxicillin combined with anti-Helicobacter pylori (Hp) for the treatment of refractory duodenal ulcer (DU), the recent healing rate and 1-year recurrence rate . Methods: 80 patients with refractory DU were randomly divided into lansoprazole group and amoxicillin group. The healing rates of the two groups were observed and compared. Lansoprazole group healing and Hp positive cases were randomly divided into maintenance group and withdrawal group. Combination of amoxicillin group ulcer healing, Hp-negative cases into the Hp eradication group, Hp positive into the Hp not eradication group; observed one-year relapse rate of 4 groups. Results: The healing rate in 4 weeks was 100% in the Lansoprazole group and 88% in the combined amoxicillin group, with no significant difference between the two groups (P> 0.05). The 1-year recurrence rate was 6% in the maintenance group (P <0.01). There was a significant difference between the two groups (P <0.01). The Hp eradication group was 5% and the Hp eradication group was 44% There was no significant difference between Hp eradication group and maintenance group (P> 0.05).